Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P10176
UPID:
COX8A_HUMAN
Alternative names:
Cytochrome c oxidase polypeptide VIII-liver/heart; Cytochrome c oxidase subunit 8-2
Alternative UPACC:
P10176; P15955
Background:
Cytochrome c oxidase subunit 8A, mitochondrial, also known as Cytochrome c oxidase polypeptide VIII-liver/heart or Cytochrome c oxidase subunit 8-2, plays a pivotal role in the mitochondrial electron transport chain. It is integral to the process of oxidative phosphorylation, facilitating the reduction of oxygen to water and thereby driving ATP synthesis. This protein is a component of cytochrome c oxidase, the last enzyme in the chain, crucial for energy production in cells.
Therapeutic significance:
The protein's association with Mitochondrial complex IV deficiency, nuclear type 15, a disorder marked by developmental delays, metabolic acidosis, and respiratory complex IV activity reduction, underscores its therapeutic significance. Understanding the role of Cytochrome c oxidase subunit 8A could open doors to potential therapeutic strategies for mitochondrial disorders.